Preclinical imaging is the most vital step in the research of living animals and drug development.
Preclinical imaging is the most vital step in the research of living animals and drug development. Over the years, imaging modalities have changed and they play a crucial part in observing changes at the cell, molecular, tissue, and organ level. Preclinical imaging that is non-invasive and in vivo has gained importance recently. It offers a visual window within the animal and enables real-time tracking of biological activities.
According to Allied Market Research, the global optical preclinical imaging market is expected to reach $859.70 million by 2030, growing at a CAGR of 5.2% from 2021 to 2030. Rise in demand for non-invasive, small animal imaging techniques, surge in funding for preclinical research by public and private organizations, and technological advancements in molecular imaging have boosted the market growth.
Preclinical imaging involves several technologies including X-ray, magnetic resonance imaging (MRI), computed tomography (CT), and optical imaging. Among these technologies, optical imaging has become more and more popular as it uses bioluminescent or fluorescent tissues or probes that are detected non-invasively in living animals. In addition, it is cost-effective, flexible, and enables ease of data interpretation.
Request for Sample Report for More Insights @ https://www.alliedmarketresearch.com/request-sample/10711
Top Leading Players:
- Berthold Technologies GmbH & Co.KG
- Endress+Hauser (Analytik Jena US LLC)
- Fujifilm Corporation (Fujifilm VisualSonics Inc.)
- LI-COR Biosciences, Inc.
- Miltenyi Biotec
- PerkinElmer, Inc.
- Rigaku Corporation (MILabs B.V.)
- TriFoil Imaging
- Vieworks Co., Ltd.
- Vilber Smart Imaging Ltd.
Use of Preclinical Optical Imaging in Cancer Diagnosis:
Due to the effectiveness of optical imaging, it gained importance in oncology research. In the niche of preclinical oncology, optical imaging allows researchers to track disease development and understand disease spread in animals throughout the period of the research study. Moreover, optical imaging is vital in measuring the presence of disease in the animal before and after the treatment by observing various timepoints in disease development. Preclinical optical imaging in oncology research allows visualization of therapeutics and other entities. Moreover, when it is used with other conventional imaging technologies including CT, X-ray, and MRI, researchers can analyze anatomical data with biological to understand the animal mechanisms at play.
Fluorescence AND BIOLUMINESCENCE IMAGING:
Preclinical optical imaging involves the use of Fluorescence and bioluminescence for imaging. An array of different fluorophores is available in the market for optical imaging. It is observed that the in vivo optical imaging using visible light is difficult as animal tissue components including hemoglobin can absorb as well as scatter light of the most visible wavelength, which limits light penetration. Thus, fluorophores are used for the emission wavelength over 680nm, which is the near-infrared portion of the light spectrum. These are ideal for imaging in vivo due to the fact that tissues are transparent at these wavelengths. On the other hand, bioluminescence refers to a biochemical reaction where an enzyme is exposed to the substrate which in turn emits light. Preclinical optical imaging has enabled several lucrative opportunities in R&D across several medical fields and has been gaining special importance in oncology.